BioSenic is an innovative company with the objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.
Our expertise is focused on bone cell therapy and the therapeutic use of arsenic trioxide (As2O3). BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for bone and autoimmune and inflammatory diseases.
BioSenic has a broad and diverse portfolio of solutions in clinical development in a variety of therapeutic areas targeting markets characterized by significant unmet medical needs and limited innovation.
2006
Served areaWorldwide
HeadquartersBâtiment H (bte 24) Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Hainaut – Belgium
31,229,152
IPOFeb. 6, 2015
Stock exchange(s)Euronext Brussels